Context Therapeutics Inc. Files 8-K: Board & Compensation Updates
Ticker: CNTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1842952
| Field | Detail |
|---|---|
| Company | Context Therapeutics Inc. (CNTX) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $55,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
TL;DR
Context Therapeutics Inc. filed an 8-K on Jan 10, 2025, detailing board changes and executive pay. #CorpGov
AI Summary
Context Therapeutics Inc. announced on January 10, 2025, changes in its board of directors and executive compensation arrangements. The filing also includes information regarding Regulation FD disclosure and financial statements. The company is incorporated in Delaware and its principal executive offices are located in Philadelphia, PA.
Why It Matters
This filing provides insight into the corporate governance and executive compensation structure of Context Therapeutics Inc., which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 001-40654 — SEC File Number (Identifies the company's filing with the SEC.)
- 86-3738787 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Context Therapeutics Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Philadelphia, Pennsylvania (location) — Principal executive offices
- January 10, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not detail the specific individuals or changes within this summary.
What are the key aspects of the compensatory arrangements mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in this summary.
What is the significance of the Regulation FD Disclosure item?
This indicates that the company is making public disclosures to prevent selective disclosure of material non-public information.
When was Context Therapeutics Inc. formerly known as Context Therapeutics LLC?
The date of the name change from Context Therapeutics LLC to Context Therapeutics Inc. was January 28, 2021.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Context Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,013 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2025-01-13 07:37:55
Key Financial Figures
- $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check
- $55,000 — to time, which currently consists of a $55,000 annual cash retainer, payable quarterly
Filing Documents
- cntx-20250110.htm (8-K) — 28KB
- a20250113-cntxpasternakrel.htm (EX-99.1) — 11KB
- image_0a.jpg (GRAPHIC) — 193KB
- 0001842952-25-000003.txt ( ) — 443KB
- cntx-20250110.xsd (EX-101.SCH) — 2KB
- cntx-20250110_lab.xml (EX-101.LAB) — 24KB
- cntx-20250110_pre.xml (EX-101.PRE) — 14KB
- cntx-20250110_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 13, 2025, the Company issued a press release announcing the appointment of Mr. Pasternak to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits Exhibit No. Description 99.1 Press Release issued by Context Therapeutics Inc., dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer